A pharmaceutical composition containing fucoidan for preventing and treating chronic atrophic gastritis

Abstract

The invention discloses a pharmaceutical composition for preventing and treating chronic atrophic gastritis. The pharmaceutical composition is prepared from the following raw materials in the following weight ratio: 14-18 parts of peach kernel, 10-14 parts of Chuanxiong rhizome, 8-12 parts of Panax notoginseng, 6-10 parts of safflower, 20-28 parts of kelp, 10-14 parts of selfheal, 15-25 parts of codonopsis pilosula, 10-14 parts of atractylodes macrocephala, 12-16 parts of fructus aurantii, 8-12 parts of amomum villosum, 12-16 parts of bupleurum, 10-18 parts of citron, and 5-10 parts of fucoidan. The pharmaceutical composition is used to treat chronic atrophic gastritis of gastric collateral blood stasis type by promoting blood circulation and removing blood stasis, unblocking meridians and relieving pain, eliminating phlegm, softening and dispersing nodules, invigorating qi and promoting qi circulation, and soothing the liver and harmonizing the stomach. The invention also discloses a preparation method of the pharmaceutical composition.

Description

Technical Field

[0001] The present invention relates to a fucoidan-containing pharmaceutical composition for preventing and treating chronic atrophic gastritis and a preparation method thereof, belonging to the field of medicine, and particularly relates to gastric collateral blood stasis type chronic atrophic gastritis. Background Art

[0002] Chronic atrophic gastritis is a type of chronic gastritis, clinically characterized by atrophy and decreased number of gastric mucosal epithelium and glands, thinning of the gastric mucosa, and the presence of intestinal metaplasia or atypical hyperplasia, also known as dysplasia. Clinically, symptoms are nonspecific, and a definitive diagnosis is generally made through gastroscopy or pathology. Common symptoms include upper abdominal pain or bloating, belching, belching, and loss of appetite, sometimes accompanied by weight loss or anemia.

[0003] Traditional Chinese Medicine (TCM) classifies chronic atrophic gastritis into six types: liver-stomach qi stagnation, liver-stomach heat stagnation, spleen-stomach weakness, spleen-stomach damp-heat, stomach yin deficiency, and blood stasis in the stomach collaterals. However, developed patent medicines are not strictly categorized, resulting in poor efficacy. Currently, Western medicine is generally used for relief, but it is ineffective for some patients. Clinical symptoms tend to recur after discontinuation of medication, and long-term use can lead to significant side effects, potentially creating a vicious cycle. There is an urgent need to develop a new Chinese medicine composition, preparation method, and application for the treatment of chronic atrophic gastritis to address these deficiencies.

[0004] Fucoidan, also known as fucoidan, fucoidan sulfate, fucoidan, and fucoidan sulfate, is primarily derived from brown algae and is a polysaccharide containing fucose and sulfate groups. It possesses a variety of biological functions, including anticoagulant, antitumor, antithrombotic, antiviral, and antioxidant properties, and enhances immune function, making it widely used in medicine and the modern food industry. The present invention combines fucoidan with traditional Chinese medicine to produce unexpected results. Summary of the Invention

[0005] The main purpose of the present application is to provide a traditional Chinese medicine composition containing fucoidan for treating chronic atrophic gastritis with good efficacy, high efficiency, short treatment course, small toxic side effects and low cost, and a preparation method thereof.

[0006] In order to achieve the above object, the present invention provides the following technical solutions:

[0007] A pharmaceutical composition containing fucoidan for preventing and treating chronic atrophic gastritis is provided. The composition is prepared from the following raw materials in the following weight proportions: 14-18 parts of peach kernel, 10-14 parts of ligusticum chuanxiong, 8-12 parts of panax notoginseng, 6-10 parts of safflower, 20-28 parts of kelp, 10-14 parts of selfheal, 15-25 parts of codonopsis pilosula, 10-14 parts of atractylodes macrocephala, 12-16 parts of fructus aurantii, 8-12 parts of amomum villosum, 12-16 parts of bupleurum, 10-18 parts of citron, and 5-10 parts of fucoidan.

[0008] The pharmaceutical composition is a preparation prepared from the following raw materials in the following weight ratio: 14 parts of peach kernel, 14 parts of Chuanxiong rhizome, 8 parts of Panax notoginseng, 10 parts of safflower, 20 parts of kelp, 14 parts of selfheal, 15 parts of codonopsis pilosula, 14 parts of atractylodes macrocephala, 12 parts of fructus aurantii, 12 parts of amomum villosum, 12 parts of bupleurum, 18 parts of citron, and 5 parts of fucoidan.

[0009] The pharmaceutical composition is a preparation prepared from the following raw materials in the following weight ratio: 18 parts of peach kernel, 10 parts of Chuanxiong, 12 parts of Panax notoginseng, 6 parts of safflower, 28 parts of kelp, 10 parts of selfheal, 25 parts of codonopsis, 10 parts of atractylodes, 16 parts of fructus aurantii, 8 parts of amomum, 16 parts of bupleurum, 10 parts of citron, and 5 parts of fucoidan.

[0010] The pharmaceutical composition is a preparation prepared from the following raw materials in the following weight ratio: 16 parts of peach kernel, 12 parts of Chuanxiong, 10 parts of Panax notoginseng, 8 parts of safflower, 24 parts of kelp, 12 parts of selfheal, 20 parts of codonopsis, 12 parts of atractylodes, 14 parts of fructus aurantii, 10 parts of amomum, 14 parts of bupleurum, 14 parts of citron, and 8 parts of fucoidan.

[0011] The pharmaceutical composition is a preparation prepared by adding raw drug powder of raw materials in various weight ratios, water or organic solvent extracts, and pharmaceutically acceptable excipients or auxiliary ingredients.

[0012] The pharmaceutical composition and the preparation are oral preparations, which are powders, granules, capsules, tablets or oral liquids.

[0013] The extraction of the pharmaceutical composition comprises the following steps: a. weighing peach kernel, chuanxiong rhizome, safflower, amomum villosum and bupleurum in respective weight proportions, extracting volatile oil and setting aside; b. adding Panax notoginseng, kelp, prunella vulgaris, codonopsis pilosula, atractylodes macrocephala, fructus aurantii and citron to the residue after extracting the volatile oil, adding water for extraction, collecting the extract and concentrating; c. adding ethanol to the concentrate, allowing the concentrate to stand, filtering and collecting the ethanol precipitate; d. uniformly mixing the ethanol precipitate and volatile oil, adding fucoidan, packaging and sterilizing to prepare an oral solution.

[0014] The extraction of the pharmaceutical composition comprises the following steps: a. weighing peach kernel, Chuanxiong rhizome, safflower, amomum villosum and bupleurum in respective weight proportions, extracting volatile oil and setting aside; b. adding Panax notoginseng, kelp, prunella vulgaris, Codonopsis pilosula, Atractylodes macrocephala, Citrus aurantium and citron to the residue after extracting the volatile oil, adding water for extraction, collecting the extract and concentrating; c. adding ethanol to the concentrate, allowing the concentrate to stand, filtering and collecting the alcohol precipitate; d. spray drying the alcohol precipitate, adding volatile oil, fucoidan and auxiliary materials, and preparing the extract into one of powder, granules, capsules and tablets.

[0015] In the pharmaceutical composition, the extraction time of volatile oil in step a is 4 hours; the water extraction conditions in step b are as follows: adding 10 times the amount of water of the medicinal material, reflux extraction twice, each extraction time is 2 hours, and the obtained extract is concentrated to a density of 1.20 g / ml; and in step c, 95% v / v ethanol aqueous solution is added to the concentrated solution to achieve an ethanol concentration of 85% v / v.

[0016] The pharmaceutical composition is used for treating chronic atrophic gastritis of gastric collateral blood stasis type.

[0017] Beneficial effects:

[0018] The development of chronic atrophic gastritis is a long-term, chronic disease process. The book "Xizhuo: The Origin and Development of Miscellaneous Diseases" states: "Fullness and distension are spleen diseases, caused by spleen qi deficiency and stagnation of qi transport and transformation, resulting in fullness and distension below the heart." This suggests that the primary pathogenesis of this disease is spleen and stomach deficiency, resulting in dysfunctional transport and transformation, and abnormal ascending and descending functions. Initial clinical findings suggest that spleen and stomach deficiency predominates. Elderly patients over 60 years old often present with a long course of illness. This condition, often affecting the collaterals and causing blood stasis, or damage to yin and fluid, leading to a lack of nourishment for the stomach, is often found in the elderly. This syndrome is one of the most common TCM syndromes of chronic atrophic gastritis. Symptoms include persistent epigastric pain, pain that is localized, resists pressure, and is stabbing, or is accompanied by hematemesis, melena, a dark purple or dark red tongue with ecchymosis, and a deep pulse. The present invention adopts peach kernel, Chuanxiong, Panax notoginseng and safflower as main drugs for promoting blood circulation, removing blood stasis, unblocking meridians and relieving pain; kelp and Prunella vulgaris for eliminating phlegm, softening and dispersing nodules, promoting diuresis and reducing swelling as assistant drugs; Codonopsis pilosula and Atractylodes macrocephala for invigorating qi, Citrus aurantium and Amomum villosum for promoting qi circulation as adjuvant drugs; Bupleurum chinense and Citron stalk for soothing liver and harmonizing stomach as guiding drugs. The whole formula is compatible. In addition, the efficacy of fucoidan in improving gastric diseases is mainly manifested in the following three aspects: (1) fucoidan has the efficacy of clearing Helicobacter pylori, inhibiting the proliferation of Helicobacter pylori and inhibiting its binding to gastric mucosa; (2) fucoidan has the efficacy of protecting gastric mucosa and treating gastric ulcers, and has a good alleviating effect on alcohol- and drug-induced gastric mucosal damage and chronic gastric ulcers; (3) fucoidan has the efficacy of resisting gastric cancer, inhibiting the proliferation of gastric cancer cells, alleviating the side effects of chemotherapy, improving the quality of life of patients, and jointly treating chronic atrophic gastritis of gastric meridian stasis type.

[0019] 2. The traditional Chinese medicine composition containing fucoidan for treating chronic atrophic gastritis of the present invention does not have any toxic side effects, has significant therapeutic effects, and does not relapse after drug withdrawal. DETAILED DESCRIPTION

[0020] Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiments are only used to illustrate the present invention and are not used in limiting the scope of the present invention.In addition, should be understood that after reading the content of the present invention record, those skilled in the art can make various changes or modifications to the present invention, but these equivalent forms fall within the scope limited by the application's appended claims equally.

[0021] Example 1: Take 16g peach kernel, 12g Chuanxiong, 10g Panax notoginseng, 8g safflower, 24g kelp, 12g selfheal, 20g Codonopsis pilosula, 12g Atractylodes macrocephala, 14g Citrus aurantium, 10g Amomum villosum, 14g Bupleurum chinense, 14g Citrus palm, and 8g fucoidan. Preparation method:

[0022] a. Weigh peach kernel, Chuanxiong, safflower, fructus amomi, and radix bupleuri in each weight ratio, and extract volatile oil. The volatile oil extraction time is 4 hours for standby use;

[0023] b. After extracting the volatile oil, add Panax notoginseng, Kelp, Prunella Vulgaris, Codonopsis pilosula, Atractylodes macrocephala, Fructus Aurantii Immaturus, and Citron to the residue, add water to extract, add 10 times the amount of water of the medicinal materials, reflux extraction 2 times, each extraction time 2h, collect the extract, and concentrate to a density of 1.20g / ml;

[0024] c. Add 95% v / v ethanol aqueous solution to the concentrate to a concentration of 85% v / v ethanol, let stand, filter, and collect the alcohol precipitate;

[0025] d. Spray-dry the alcohol precipitation solution, add volatile oil, fucoidan and auxiliary materials to prepare granules.

[0026] Example 2: Take 14g peach kernel, 14g Chuanxiong, 8g Panax notoginseng, 10g safflower, 20g kelp, 14g selfheal, 15g Codonopsis pilosula, 14g Atractylodes macrocephala, 12g Citrus aurantium, 12g Amomum villosum, 12g Bupleurum chinense, 18g citron, 5g fucoidan, preparation method:

[0027] a. Weigh peach kernel, Chuanxiong rhizome, safflower, Amomum villosum and bupleurum in each weight ratio, extract volatile oil, and extract volatile oil for 4 hours;

[0028] b. After extracting the volatile oil, add Panax notoginseng, Kelp, Prunella Vulgaris, Codonopsis pilosula, Atractylodes macrocephala, Fructus Aurantii Immaturus, and Citron to the residue, add water to extract, add 10 times the amount of water of the medicinal materials, reflux extraction 2 times, each extraction time 2h, collect the extract, and concentrate to a density of 1.20g / ml;

[0029] c. Add 95% v / v ethanol aqueous solution to the concentrate to a concentration of 85% v / v ethanol, let stand, filter, and collect the alcohol precipitate;

[0030] d. Evenly mix the alcohol precipitate and volatile oil, dispense into 10 ml oral liquid bottles, add fucoidan, seal, and sterilize by flowing steam sterilization (100° C.) for 30 min to obtain the oral liquid of the present invention.

[0031] Example 3: Take 18g of peach kernel, 10g of Chuanxiong, 12g of Panax notoginseng, 6g of safflower, 28g of kelp, 10g of selfheal, 25g of Codonopsis pilosula, 10g of Atractylodes macrocephala, 16g of Citrus aurantium, 8g of Amomum villosum, 16g of Bupleurum chinense, 10g of citron, and 10g of fucoidan. Preparation method:

[0032] a. Weigh peach kernel, Chuanxiong rhizome, safflower, Amomum villosum and bupleurum in each weight ratio, extract volatile oil, and extract volatile oil for 4 hours;

[0033] b. After extracting the volatile oil, add Panax notoginseng, Kelp, Prunella Vulgaris, Codonopsis pilosula, Atractylodes macrocephala, Fructus Aurantii Immaturus, and Citron to the residue, add water to extract, add 10 times the amount of water of the medicinal materials, reflux extraction 2 times, each extraction time 2h, collect the extract, and concentrate to a density of 1.20g / ml;

[0034] c. Add 95% v / v ethanol aqueous solution to the concentrate to a concentration of 85% v / v ethanol, let stand, filter, and collect the alcohol precipitate;

[0035] d. Spray-dry the alcohol precipitate, add volatile oil, fucoidan and excipients to prepare capsules.

[0036] Example 4: Pharmacodynamics Study

[0037] An anhydrous ethanol-induced acute gastric mucosal injury model in rats was used. Through gross observation of the rats' gastric mucosa, tests such as serum inflammatory factors and gastric tissue oxidative stress indicators, the efficacy of the present invention on the ethanol-induced gastric mucosal injury rat model and its possible involvement mechanism were studied, providing data support for health foods that improve gastric mucosal function and promoting the development of the pharmaceutical and food industries.

[0038] 1 Materials and Instruments

[0039] 1.1 Instrument

[0040] Table 1 Main instruments for the experiment

[0041]

[0042]

[0043] Table 2 Experimental reagents

[0044]

[0045] 1.2 Experimental animals

[0046] Forty-eight healthy male SPF Sprague-Dawley (SD) rats, 6-8 weeks old, weighing 180-220 g, were purchased from Hangzhou Medical College with animal production license number: SCXK (Zhejiang) 2019-0002.

[0047] Housing: Mice were housed at Xiamen Medical College with free access to food and water. Room temperature was maintained at 22–23°C with adequate ventilation. Animal experiments were approved by the Ethics Committee of Xiamen Medical College for Animal Experimentation (Approval No. 230424003). All experimental procedures complied with ethical requirements for animal experimentation.

[0048] 2 Experimental methods

[0049] 2.1 Animal modeling

[0050] 48 healthy male SPF grade SD rats were adaptively raised for 3 days and randomly divided into normal group, model group, positive drug potassium citrate group and low, medium and high dose groups of the present invention, with 8 rats in each group. Wherein the normal group and model group were gavaged and given 10mL / kg of normal saline every day, and potassium citrate group gave potassium citrate 108mg / kg, and low, medium and high dose groups of the present invention were respectively given 5,10,20g crude drug / kg (calculated by the weight of fucoidan) granule aqueous solution prepared by embodiment 1 of the present invention, and were administered continuously for 7 days. Fasting was performed 1 day before the last administration, and 2h after the last administration, all the other rats in the normal group were gavaged with 5mL / kg absolute ethanol to set up alcoholic gastric ulcer model, and blood was taken from the eyeball after 1h, and rats were killed by cervical dislocation method, and the abdomen was cut open to take out the stomach, cut along the greater curvature of the stomach, and cleaned with normal saline to no contents and bloodshot, placed on ice box and flattened, observed. The stomach was divided into two parts, and one half was divided into two parts and fixed in 4% paraformaldehyde solution. The remaining stomach tissue was divided into four parts and stored in a -80°C refrigerator for future use.

[0051] 2.2 Gross observation of gastric mucosa and injury assessment

[0052] One hour after modeling with anhydrous ethanol, rats were sacrificed by cervical dislocation. The abdominal cavity was opened, and the stomach tissue was isolated. The stomach was cut open along the greater curvature and washed with normal saline until the contents and blood were removed. The tissue was then flattened on an ice box for observation. Lesion length was measured using a vernier caliper under a stereomicroscope, and the extent of gastric mucosal damage was calculated. Scoring criteria were based on the Guth scoring system (see Table 3).

[0053] Table 3 Scoring criteria for gastric mucosal injury

[0054]

[0055] The sum of all scores was used to determine the gastric mucosal ulcer index of each rat. The gastric mucosal injury inhibition rate of each drug-treated group was calculated using the following formula.

[0056]

[0057] 2.3 Determination of antioxidant indicators in rat gastric mucosa

[0058] Rinse the gastric tissue with 0.9% saline, blot dry with filter paper, and weigh. Mix the gastric tissue with saline at a mass ratio of 1:9 and grind using a tissue crusher to prepare a 10% gastric tissue homogenate. Centrifuge at 3000 rpm. Remove the supernatant, aliquot, and store at -80°C. Assay the gastric tissue homogenate for MDA content, SOD, and GSH-Px activity according to the kit instructions. See Tables 4, 5, and 6 for the steps.

[0059] Table 4 MDA test box operation steps

[0060]

[0061] Use a needle to poke a small hole in the centrifuge lid, close the lid, mix thoroughly, and incubate in a 95°C water bath for 40 minutes. Remove and cool to room temperature under running water. Centrifuge at 4000 rpm for 10 minutes. Collect 0.2 mL of the supernatant and measure the absorbance of each well at 532 nm using a microplate reader.

[0062] Table 5 SOD test kit operation steps

[0063]

[0064]

[0065] Table 6 GSH-Px test kit operation steps

[0066]

[0067] 2.4 Determination of inflammatory factors in rat serum

[0068] The rat blood was placed at room temperature for two hours and then centrifuged at 4000 rpm for 10 minutes to obtain serum, which was then dispensed into EP tubes and stored at -80°C for later use. The levels of inflammatory factors in the rat serum were measured using enzyme-linked immunosorbent assay (ELISA).

[0069] ELISA kit instructions: Select the desired entry, add 100 μL of sample or standard to each well, add 50 μL of detection antibody, mix well, and incubate at 37°C for 90 minutes. Wash the plate after the final wash and tap dry on filter paper. Add 100 μL of Streptavidin-HRP working solution to each well, incubate at 37°C for 30 minutes, wash the plate, and finally add TMB for color development. Incubate at 37°C in the dark. Terminate the reaction by the color intensity of the wells. Add Stop Solution to terminate the reaction and measure absorbance at 450 nm on a microplate reader.

[0070] 2.5 Statistical analysis

[0071] SPSS statistical software was used to analyze the data in this chapter, and the results were expressed as mean ± standard deviation. When the experimental data conformed to a normal distribution and had homogeneous variances, one-way analysis of variance with the LSD test was used for statistical analysis; when the variances were unequal, one-way analysis of variance with the Games-Howell test was used for statistical analysis. P < 0.05 was considered statistically significant.

[0072] 2 Results

[0073] 2.1 Gross observation of gastric mucosa and injury assessment

[0074] The results showed that the gastric mucosa of rats in the blank normal group was ruddy and without congestion; the gastric mucosa of rats in the model group was locally swollen, with clearly visible bleeding bands and severe congestion; the number of gastric mucosal bleeding bands in the potassium citrate group and the low-dose groups of the present invention was significantly reduced, with slight local congestion; the gastric mucosa of the high-dose group of the present invention was relatively ruddy, with no bleeding bands and a small number of bleeding spots.

[0075] Compared with the blank group, the gastric mucosal ulcer index of rats in the model group increased (P < 0.01). Compared with the model group, the gastric mucosal ulcer index of rats after pre-administration of bismuth potassium citrate and the present invention was significantly reduced (P < 0.01). Comparison between the high, medium, and low dose groups of the experiment showed that the high dose group was different from the medium and low dose groups (P < 0.05), and there was no significant difference between the medium and low dose groups. See Table 7.

[0076] Table 7 Effect of the present invention on ethanol-induced gastric mucosal ulcer index in rats ( n=8)

[0077]

[0078]

[0079] Note: ## P < 0.01 vs blank group; **P < 0.01 vs model group; △ P<0.05 vs the high-dose group of the present invention 2.2 Effect of the present invention on antioxidant indicators in gastric tissue of rats with acute gastric mucosal injury model

[0080] Compared with the blank group, the MDA content in the gastric mucosal tissue of rats in the model group was significantly increased (P<0.01). After preventive administration of potassium bismuth citrate and different doses of the present invention, the MDA content in the gastric mucosal tissue of rats in the positive group and the experimental high-dose group was significantly reduced compared with the model group (P<0.01), the MDA content in the gastric mucosal tissue of rats in the medium-dose group was significantly reduced (P<0.05), and the MDA content in the low-dose group was reduced but not significantly. Compared with the blank group, the SOD activity in the gastric tissue of rats in the model group was significantly decreased (P<0.01). After preventive administration of potassium bismuth citrate and different doses of the present invention, the SOD activity in the gastric mucosal tissue of rats in the positive group and the experimental high- and medium-dose groups was increased compared with the model group (P<0.01), and the SOD activity in the gastric mucosal tissue of rats in the low-dose group was significantly increased (P<0.05). Compared with the blank group, the GSH-Px activity in the gastric mucosal tissue of rats in the model group was significantly decreased (P < 0.01). After preventive administration of potassium bismuth citrate and different doses of the present invention, the GSH-Px activity in the gastric mucosal tissue of rats in the positive group and the high- and medium-dose experimental groups was significantly increased compared with the model group (P < 0.01). Although GSH-Px activity in the low-dose group increased, it was not significant. See Table 8.

[0081] Table 8 Effect of the present invention on the levels of MDA, SOD and GSH-Px in gastric mucosal tissue of rats with gastric mucosal injury induced by ethanol ( n=8)

[0082]

[0083] Note: ## P < 0.01 vs blank group; ** P < 0.01, * P<0.05vs model group 2.3 Effect of the present invention on serum inflammatory factors in rats with acute gastric mucosal injury model

[0084] Compared with the blank group, the serum TNF-α level of rats in the model group was significantly increased (P < 0.01). After the preventive administration of potassium bismuth citrate and different doses of the present invention, the serum TNF-α levels of rats in the positive group and experimental group were reduced compared with the model group (P < 0.01 or P < 0.05). Compared with the blank group, the serum IL-1β level of rats in the model group was significantly increased (P < 0.01). After the preventive administration of potassium bismuth citrate and different doses of the present invention, the serum IL-1β levels of rats in the positive group and the experimental high and medium dose groups were reduced compared with the model group (P < 0.01 or P < 0.05). Although the IL-1β level in the low-dose group was reduced, it was not significant. See Table 9.

[0085] Table 9 Effect of the present invention on the levels of TNF-α and IL-1β in the serum of rats with gastric mucosal injury induced by ethanol ( n=8)

[0086]

[0087] Note: ## P < 0.01 vs blank group; ** P < 0.01, # P<0.05vs model group 3 discussion and summary

[0088] Ethanol is a common factor that causes gastric mucosal damage. It has a strong corrosive effect on the gastric mucosa, destroying the surface mucus layer and mucous cells while also weakening the protective effects of gastric mucosal defense factors. To investigate the protective mechanism of the present invention against gastric mucosal damage in rats, this study selected gross observations and biochemical indicators of gastric mucosal defense mechanisms, namely malondialdehyde (MDA) content, superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, and tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) levels. After pre-administration of the present invention and potassium bismuth citrate to rats, the results showed that the present invention significantly reduced ethanol-induced hemorrhagic damage to rat gastric mucosal tissue and improved the injury inhibition rate. MDA content in the gastric mucosa was significantly reduced, while SOD and GSH-Px activity was significantly increased, and TNF-α and IL-1β levels were reduced, suggesting that its mechanism of action may be related to enhancing antioxidant capacity, enhancing gastric mucosal protective factors, and reducing inflammatory factors. In summary, oxidative stress and inflammatory responses can lead to acute gastric mucosal damage. Different doses of the present invention can effectively alleviate ethanol-induced gastric mucosal damage in rats, enhance antioxidant activity, and reduce inflammation, thereby protecting the gastric mucosa. This study provides a reference for the development of functional products for alcohol-induced gastric mucosal damage.

[0089] The foregoing description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention shall be included within the scope of protection of the present invention. Although the embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions, and variations may be made to these embodiments without departing from the principles and spirit of the present invention. The scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A pharmaceutical composition containing fucoidan for preventing and treating chronic atrophic gastritis, characterized by: The preparation is prepared from the following raw materials in the following weight proportions: 14-18 parts of peach kernel, 10-14 parts of Chuanxiong, 8-12 parts of Panax notoginseng, 6-10 parts of safflower, 20-28 parts of kelp, 10-14 parts of selfheal, 15-25 parts of codonopsis pilosula, 10-14 parts of atractylodes macrocephala, 12-16 parts of fructus aurantii, 8-12 parts of amomum villosum, 12-16 parts of bupleurum, 10-18 parts of citron, and 5-10 parts of fucoidan.

2. The pharmaceutical composition according to claim 1, wherein: It is A preparation prepared from the following raw materials in the following weight ratio: 14 parts of peach kernel, 14 parts of Chuanxiong, 8 parts of Panax notoginseng, 10 parts of safflower, 20 parts of kelp, 14 parts of selfheal, 15 parts of codonopsis, 14 parts of atractylodes, 12 parts of fructus aurantii, 12 parts of amomum, 12 parts of bupleurum, 18 parts of citron, and 5 parts of fucoidan.

3. The pharmaceutical composition according to claim 1, wherein: The preparation is prepared from the following raw materials in the following weight proportions: 18 parts of peach kernel, 10 parts of Chuanxiong rhizome, 12 parts of Panax notoginseng, 6 parts of safflower, 28 parts of kelp, 10 parts of selfheal, 25 parts of codonopsis pilosula, 10 parts of atractylodes macrocephala, 16 parts of fructus aurantii, 8 parts of amomum villosum, 16 parts of bupleurum root, 10 parts of citron, and 5 parts of fucoidan.

4. The pharmaceutical composition according to claim 1, wherein: The preparation is prepared from the following raw materials in the following weight proportions: 16 parts of peach kernel, 12 parts of Chuanxiong rhizome, 10 parts of Panax notoginseng, 8 parts of safflower, 24 parts of kelp, 12 parts of selfheal, 20 parts of codonopsis pilosula, 12 parts of atractylodes macrocephala, 14 parts of fructus aurantii, 10 parts of amomum villosum, 14 parts of bupleurum root, 14 parts of bergamot, and 8 parts of fucoidan.

5. The pharmaceutical composition according to claim 1, wherein: The preparation is prepared by adding pharmaceutically acceptable auxiliary materials to the raw drug powder of the raw drug in various weight proportions, water or organic solvent extracts.

6. The pharmaceutical composition according to claim 1, wherein: The preparation is an oral preparation, which is one of powder, granule, capsule, tablet or oral liquid.

7. The pharmaceutical composition according to claim 1, wherein: The extraction method comprises the following steps: a. weighing peach kernel, Chuanxiong rhizome, safflower, amomum villosum and bupleurum root in respective weight proportions, extracting volatile oil and setting aside; b. adding Panax notoginseng, kelp, prunella vulgaris, Codonopsis pilosula, Atractylodes macrocephala, Citrus aurantium and bergamot to the residue after extracting the volatile oil, adding water to extract, collecting the extract and concentrating it; c. Add ethanol to the concentrated solution, let it stand, filter, and collect the alcohol precipitate; d. Evenly mix the alcohol precipitate and volatile oil, add fucoidan, divide into packages, sterilize, and prepare oral solution.

8. The pharmaceutical composition according to claim 1, wherein: The extraction method comprises the following steps: a. weighing peach kernel, Chuanxiong rhizome, safflower, amomum villosum and bupleurum root in respective weight proportions, extracting volatile oil and setting aside; b. adding Panax notoginseng, kelp, prunella vulgaris, Codonopsis pilosula, Atractylodes macrocephala, Citrus aurantium and bergamot to the residue after extracting the volatile oil, adding water to extract, collecting the extract and concentrating it; c. adding ethanol to the concentrated solution, allowing it to stand, filtering, and collecting the alcohol precipitate; d. spray-drying the alcohol precipitate, adding volatile oil, fucoidan, and auxiliary materials to prepare a powder, granules, capsules, or tablets.

9. The pharmaceutical composition according to claim 7 or 8, wherein: The extraction time of volatile oil in step a is 4 hours; the water extraction conditions in step b are as follows: adding 10 times the weight of water of the medicinal material, reflux extraction twice, each extraction time is 2 hours, and the obtained extract is concentrated to a density of 1.20g / ml; in step c, 95% v / v ethanol aqueous solution is added to the concentrated solution to achieve an ethanol concentration of 85% v / v.

10. The pharmaceutical composition according to claim 1, wherein: Chronic atrophic gastritis is of the gastric collateral blood stasis type.

Images